NASDAQ · RXRX
Healthcare · Biotechnology
$3.68
Up+$0.24 (+6.39%)
Updated Nov 4, 2026, 6:01 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · RXRX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
RXRX closed at $3.68 after 21 trading sessions, down 20.52% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $3.855 | $4.08 | $3.65 | $3.68 | 20.81M |
| Nov 2, 2026 | $4.11 | $4.17 | $3.78 | $3.83 | 22.57M |
| Oct 30, 2026 | $4.05 | $4.1595 | $3.7847 | $4.03 | 24.41M |
| Oct 29, 2026 | $4.25 | $4.515 | $4.15 | $4.24 | 20.96M |
| Oct 28, 2026 | $4.00 | $4.43 | $3.9927 | $4.35 | 28.5M |
| Oct 27, 2026 | $3.81 | $4.145 | $3.7301 | $4.05 | 22.17M |
| Oct 26, 2026 | $3.71 | $3.86 | $3.64 | $3.80 | 16.1M |
| Oct 23, 2026 | $3.52 | $3.70 | $3.45 | $3.70 | 19.08M |
| Oct 22, 2026 | $3.54 | $3.68 | $3.485 | $3.58 | 17.74M |
| Oct 21, 2026 | $3.66 | $3.76 | $3.56 | $3.64 | 19.36M |
| Oct 20, 2026 | $3.555 | $3.67 | $3.47 | $3.66 | 20.93M |
| Oct 19, 2026 | $3.53 | $3.69 | $3.48 | $3.61 | 30.01M |
| Oct 16, 2026 | $4.11 | $4.185 | $3.44 | $3.465 | 40.72M |
| Oct 15, 2026 | $3.65 | $4.41 | $3.53 | $4.16 | 62.87M |
| Oct 14, 2026 | $3.72 | $3.91 | $3.66 | $3.74 | 18.78M |
| Oct 13, 2026 | $4.01 | $4.05 | $3.82 | $3.835 | 19.76M |
| Oct 12, 2026 | $4.31 | $4.365 | $3.91 | $4.01 | 23.79M |
| Oct 9, 2026 | $4.015 | $4.43 | $3.89 | $4.36 | 35.5M |
| Oct 8, 2026 | $4.19 | $4.20 | $3.79 | $3.95 | 30.9M |
| Oct 7, 2026 | $4.505 | $4.60 | $4.23 | $4.27 | 40.73M |
| Oct 6, 2026 | $4.81 | $5.19 | $4.395 | $4.63 | 71.11M |
The latest Smart Investors Daily articles mentioning RXRX.
Company
Market Activity
Research & News
RXRX research
Company profile and research snapshot.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | Needham | Buy | — |
| May 14, 2026 | Morgan Stanley | Equal-Weight | — |
| May 7, 2026 | Needham | Buy | — |
| Apr 30, 2026 | JP Morgan | Overweight | — |
| Feb 26, 2026 | B of A Securities | Neutral | — |
No generated briefing is available yet.
SeekingAlpha · Nov 3, 2026
Recursion Pharmaceuticals, Inc. (RXRX) Q3 2026 Earnings Call November 3, 2026 8:00 AM ESTCompany ParticipantsNajat Khan - CEO, President & DirectorVicki...
Yahoo · Nov 3, 2026
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Monday reported a loss of $119 million in its third quarter.
Yahoo · Nov 2, 2026
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +8.33% and +69.88%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Nov 2, 2026
New Phase 2 REC-4881 data presented at CGA-IGC in an expanded adult population aged 18 years and older show deep, durable polyp burden reductions in FAP, with activity throughout the GI tract and in larger, higher-risk polyps.REC-4881 shows deep activity throughout the GI tract in post colectomy patients, including near-clearance: After 12 weeks of treatment, nearly 1 in 2 patients in the upper GI and more than 1 in 3 in the lower GI achieved polyp burden reductions of ≥65%. Two patients achieve
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RXRX.
